Premium
A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5‐fluorouracil, doxorubicin, and cisplatin
Author(s) -
Cullinan Stephen,
Moertel Charles G.,
Wieand Harry S.,
Schutt Allan J.,
Krook James E.,
Foley John F.,
Norris Brian D.,
Kardinal Carl G.,
Tschetter Loren K.,
Barlow John F.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900515)65:10<2207::aid-cncr2820651007>3.0.co;2-y
Subject(s) - medicine , regimen , fluorouracil , vincristine , chemotherapy , gastroenterology , doxorubicin , cyclophosphamide , oncology , cisplatin , surgery
One hundred eighty‐seven patients with histologically proven advanced pancreatic adenocarcinoma were randomly assigned to therapy with 5‐fluorouracil (5‐FU) alone, to the Mallinson regimen (combined and sequential 5‐FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C), or to combined 5‐FU, doxorubicin, and cisplatin (FAP). Patients with both measurable and nonmeasurable disease were included and the primary study end point was survival. Among 41 patients with measurable disease, objective response rates were 7% for 5‐FU alone, 21% for the Mallinson regimen, and 15% for FAP. The median interval to progression for each of the three regimens was 2.5 months. Survival curves intertwined with the median survival times for 5‐FU alone and the Mallinson regimen at 4.5 months and for FAP at 3.5 months. Compared with 5‐FU alone, both the Mallinson regimen and FAP produced significantly more toxicity. Neither the Mallinson regimen nor FAP can be recommended as therapy for advanced pancreatic carcinoma. Any chemotherapy for this disease should remain an experimental endeavor.